CPIG
VRNA

Chicago Partners Investment Group’s Verona Pharma VRNA Stock Holding History

Chicago Partners Investment Group’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,006
Closed -$58K – 600
2021
Q2 		$58K Buy
+10,006
New +$69.4K ﹤0.01% 527

Other funds holding VRNA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Chicago Partners Investment Group's VRNA Position: Q3 2021 in Review

Chicago Partners Investment Group sold out of Verona Pharma (VRNA) in Q3 2021, closing a stake of 10,006 shares — an estimated $58K sold.

Chicago Partners Investment Group first reported a position in VRNA in Q2 2021 and held it in 1 quarter. The position peaked at $58K in Q2 2021. 40 funds tracked by Wall St. Rank hold VRNA as of Q3 2021.

  • Chicago Partners Investment Group reported no remaining Verona Pharma position as of Q3 2021 after selling out during the quarter.
  • Chicago Partners Investment Group sold 10,006 Verona Pharma shares in Q3 2021, an estimated $58K.
  • Chicago Partners Investment Group first reported a position in Verona Pharma in Q2 2021 and held it in 1 quarter.
  • Chicago Partners Investment Group's Verona Pharma position peaked at $58K in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2021.

Based on Chicago Partners Investment Group's 13F filing for Q3 2021, filed 12 Nov 2021.